LY294002 induces in vitro apoptosis and overexpression of p75NTR in human uterine leiomyosarcoma HTB 114 cells

References

• Arévalo JC, Wu SH. 2006. Neurotrophin signaling: Many exciting surprises! Cell Mol Life Sci 63:1523–1537
   PubMed Web of Science ®Google Scholar
• Barrett GL. 2000. The p75 neurotrophin receptor and neuronal apoptosis. Prog Neurobiol 61:205–229
   PubMed Web of Science ®Google Scholar
• Bilderback TR, Gazula VR, Dobrowsky RT. 2001. Phosphoinositide 3-kinase regulates crosstalk between Trk A tyrosine kinase and p75(NTR)-dependent sphingolipid signaling pathways. J Neurochem 76:1540–1551
   PubMed Web of Science ®Google Scholar
• Bredesen DE, Ye X, Tasinato A, Sperandio S, Wang JJ, Assa-Munt N, Rabizadeh S. 1998. p75NTR and the concept of cellular dependence: Seeing how the other half die. Cell Death Differ 5:365–371
   PubMed Web of Science ®Google Scholar
• Brown RE, Zhang PL, Lun M, Zhu S, Pellitteri PK, Riefkohl W, Law A, et al. 2006. Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma. Ann Clin Lab Sci 36:273–282
   PubMed Web of Science ®Google Scholar
• Brown RE, Zotalis G, Zhang PL, Zhao B. 2008. Morphoproteomic confirmation of a constitutively activated mTOR pathway in high grade prostatic intraepithelial neoplasia and prostate cancer. Int J Clin Exp Pathol 1:333–342
   PubMed Web of Science ®Google Scholar
• Choi HS, Rucker PV, Wang Z, Fan Y, Albaugh P, Chopiuk G, Gessier F, et al. 2015. (R)-2-phenylpyrrolidine substituted imidazopyridazines: A new class of potent and selective pan-TRK inhibitors. ACS Med Chem Lett 6:562–567
   PubMed Web of Science ®Google Scholar
• D’Angelo E, Prat J. 2010. Uterine sarcomas: A review. Gynecol Oncol 116:131–139
   PubMed Web of Science ®Google Scholar
• Dinh TA, Oliva EA, Fuller AF Jr, Lee H, Goodman A. 2004. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990–1999) at the Massachusetts General Hospital. Gynecol Oncol 92:648–652
   PubMed Web of Science ®Google Scholar
• Feng W, Brown RE, Trung CD, Li W, Wang L, Khoury T, Alrawi S, et al. 2008. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma. Ann Clin Lab Sci 38:195–209
   PubMed Web of Science ®Google Scholar
• Feng W, Duan X, Liu J, Xiao J, Brown RE. 2009. Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions. Int J Clin Exp Pathol 2:249–260
   PubMed Web of Science ®Google Scholar
• Ghayad SE, Cohen PA. 2010. Inhibitors of the PI3K/Akt/mTOR pathway: New hope for breast cancer patients. Recent Pat Anticancer Drug Discov 5:29–57
   PubMed Web of Science ®Google Scholar
• Holgado-Madruga M, Moscatello DK, Emlet DR, Dieterich R, Wong AJ. 1997. Grb2-associated binder-1 mediates phosphatidylinositol 3-kinase activation and the promotion of cell survival by nerve growth factor. Proc Natl Acad Sci U S A 94:12419–12424
   PubMed Web of Science ®Google Scholar
• Hu X, Pandolfi PP, Li Y, Koutcher JA, Rosenblum M, Holland EC. 2005. mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia 7:356–368
   PubMed Web of Science ®Google Scholar
• Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. 2000. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 6:880–886
   PubMed Web of Science ®Google Scholar
• Knowles MA, Platt FM, Ross RL, Hurst CD. 2009. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev 28:305–316
   PubMed Web of Science ®Google Scholar
• Lee CM, Fuhrman CB, Planelles V, Peltier MR, Gaffney DK, Soisson AP, Dodson MK, et al. 2006. Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clin Cancer Res 12:250–256
   PubMed Web of Science ®Google Scholar
• Levi-Montalcini R, Hamburger V. 1951. Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J Exp Zool 116:321–361
   PubMedGoogle Scholar
• Li W, Tan D, Zhang Z, Liang JJ, Brown RE. 2008. Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma. Oncol Rep 20:713–719
   PubMed Web of Science ®Google Scholar
• Lin F, Zhang PL, Yang XJ, Prichard JW, Lun M, Brown RE. 2006. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. Ann Clin Lab Sci 36:283–293
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Chiorean EG, Harris WB, Von Hoff DD, Stejskal-Barnett A, Qi W, Anthony SP, et al. 2012. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur J Cancer 48:3319–3327
   PubMed Web of Science ®Google Scholar
• Molloy NH, Read DE, Gorman AM. 2011. Nerve growth factor in cancer cell death and survival. Cancers 3:510–530
   PubMedGoogle Scholar
• Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
   PubMed Web of Science ®Google Scholar
• Pula G, Pistilli A, Montagnoli C, Stabile AM, Rambotti MG, Rende M. 2013. The tricyclic antidepressant amitriptyline is cytotoxic to HTB114 human leiomyosarcoma and induces p75(NTR)-dependent apoptosis. Anticancer Drugs 24:899–910
   PubMed Web of Science ®Google Scholar
• Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, Tateo S, et al. 2008. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 44:808–818
   PubMed Web of Science ®Google Scholar
• Reichardt P. 2012. The treatment of uterine sarcomas. Ann Oncol 23:151–157
   Web of Science ®Google Scholar
• Rende M, Brizi E, Conner J, Treves S, Censier K, Provenzano C, Taglialatela G, et al. 2000. Nerve growth factor (NGF) influences differentiation and proliferation of myogenic cells in vitro via TrKA. Int J Dev Neurosci 18:869–885
   PubMed Web of Science ®Google Scholar
• Rende M, Pistilli A, Stabile AM, Terenzi A, Cattaneo A, Ugolini G, Sanna P. 2006. Role of NGF and its receptors in non-nervous cancer growth: Efficacy of a tyrosine kinase inhibitor (AG879) and neutralizing antibodies anti-TrKA and anti-NGF: An in vitro and in vivo study. Anticancer Drugs 17:929–941
   PubMed Web of Science ®Google Scholar
• Segal RA, Greenberg ME. 1996. Intracellular signaling pathways activated by neurotrophic factors. Annu Rev Neurosci 19:463–489
   PubMed Web of Science ®Google Scholar
• Stabile AM, Montagnoli C, Pistilli A, Rambotti MG, Pula G, Rende M. 2013. Antiproliferative and pro-apoptotic effects of the Trk-inhibitor GW441756 in human myosarcomas and prostatic carcinoma. Curr Signal Transduct Ther 8:74–83
   Web of Science ®Google Scholar
• Vaishnavi A, Le AT, Doebele RC. 2015. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 5:25–34
   PubMed Web of Science ®Google Scholar
• Vlahos CJ, Matter WF, Hui KY, Brown RF. 1994. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269:5241–5248
   PubMed Web of Science ®Google Scholar
• Wang W, Chen J, Guo X. 2014. The role of nerve growth factor and its receptors in tumorigenesis and cancer pain. Biosci Trends 8:68–74
   PubMed Web of Science ®Google Scholar